EA201692350A1 - Биомаркеры легочной гипертензии - Google Patents
Биомаркеры легочной гипертензииInfo
- Publication number
- EA201692350A1 EA201692350A1 EA201692350A EA201692350A EA201692350A1 EA 201692350 A1 EA201692350 A1 EA 201692350A1 EA 201692350 A EA201692350 A EA 201692350A EA 201692350 A EA201692350 A EA 201692350A EA 201692350 A1 EA201692350 A1 EA 201692350A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pulmonary hypertension
- ccl21
- biomarkers
- modeling
- biomarker
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 6
- 239000000090 biomarker Substances 0.000 title abstract 2
- 102100036846 C-C motif chemokine 21 Human genes 0.000 abstract 3
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 238000010837 poor prognosis Methods 0.000 abstract 1
- 208000037821 progressive disease Diseases 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170962 | 2014-06-03 | ||
| PCT/IB2015/054082 WO2015186037A1 (en) | 2014-06-03 | 2015-05-29 | Pulmonary hypertension biomarker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201692350A1 true EA201692350A1 (ru) | 2017-04-28 |
Family
ID=50842165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201692350A EA201692350A1 (ru) | 2014-06-03 | 2015-05-29 | Биомаркеры легочной гипертензии |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170088897A1 (enExample) |
| EP (1) | EP3152327B1 (enExample) |
| JP (1) | JP6622722B2 (enExample) |
| KR (1) | KR20170013261A (enExample) |
| CN (1) | CN106460059B (enExample) |
| AU (1) | AU2015270185B2 (enExample) |
| CA (1) | CA2950527A1 (enExample) |
| EA (1) | EA201692350A1 (enExample) |
| ES (1) | ES2747381T3 (enExample) |
| MX (1) | MX2016015930A (enExample) |
| WO (1) | WO2015186037A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170088897A1 (en) | 2014-06-03 | 2017-03-30 | Novartis Ag | Pulmonary hypertension biomarker |
| EP3537962A4 (en) * | 2016-11-10 | 2019-11-27 | Auburn University | METHOD AND SYSTEM FOR ASSESSING BLOOD VESSELS |
| CN106978485A (zh) * | 2017-03-22 | 2017-07-25 | 首都医科大学 | 卵泡抑素样蛋白1对肺动脉高压的保护作用 |
| EP3624821A4 (en) * | 2017-05-19 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION |
| CN107436333B (zh) * | 2017-09-05 | 2019-12-20 | 中国医学科学院阜外医院 | 精胺作为标志物在制备肺动脉高压的诊断产品中的应用及医疗器械 |
| BR112023019066A2 (pt) * | 2021-03-25 | 2023-10-17 | Chugai Pharmaceutical Co Ltd | Método para selecionar pacientes com hipertensão arterial pulmonar e biomarcador |
| CN113493829B (zh) * | 2021-09-09 | 2021-11-12 | 中日友好医院(中日友好临床医学研究所) | 生物标志物在肺动脉高压诊疗中的应用 |
| CN115558711A (zh) * | 2022-08-02 | 2023-01-03 | 上海市肺科医院 | 肺动脉高压生物标志物 |
| CN116148471B (zh) * | 2022-11-01 | 2024-05-07 | 中南大学 | 肺动脉高压的生物标志物及其应用 |
| CN119193817A (zh) * | 2024-11-15 | 2024-12-27 | 赣南医科大学第一附属医院 | 一种评估先天性心脏病相关肺动脉高压不可逆的生物标志物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US20060019272A1 (en) * | 2004-05-03 | 2006-01-26 | The Regents Of The University Of Colorado | Diagnosis of disease and monitoring of therapy using gene expression analysis of peripheral blood cells |
| JP4657757B2 (ja) * | 2005-02-23 | 2011-03-23 | 株式会社膠原病研究所 | 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療 |
| CA2678258A1 (en) * | 2007-02-09 | 2008-08-14 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
| KR101362951B1 (ko) * | 2007-04-26 | 2014-02-28 | 동국대학교 산학협력단 | 기미 형성 예지방법 및 기미 형성 예지용 진단 키트 |
| US20120295797A1 (en) * | 2008-04-02 | 2012-11-22 | Jones Peter L | Methods for diagnosis and prognosis of pulmonary hypertension |
| CN101318932A (zh) * | 2008-07-15 | 2008-12-10 | 东华大学 | 2′-羧基-5′-氟联苯衍生物、其制备及应用 |
| WO2011080050A2 (en) * | 2009-12-11 | 2011-07-07 | Novartis Ag | Binding molecules |
| CA2832565A1 (en) * | 2011-04-08 | 2012-10-11 | Biogen Idec Ma Inc. | Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof |
| GB201118840D0 (en) * | 2011-11-01 | 2011-12-14 | Univ Sheffield | Pulmonary hypertension II |
| US20170088897A1 (en) | 2014-06-03 | 2017-03-30 | Novartis Ag | Pulmonary hypertension biomarker |
-
2015
- 2015-05-29 US US15/315,908 patent/US20170088897A1/en not_active Abandoned
- 2015-05-29 CN CN201580029136.8A patent/CN106460059B/zh active Active
- 2015-05-29 EP EP15731117.6A patent/EP3152327B1/en active Active
- 2015-05-29 MX MX2016015930A patent/MX2016015930A/es unknown
- 2015-05-29 AU AU2015270185A patent/AU2015270185B2/en not_active Ceased
- 2015-05-29 WO PCT/IB2015/054082 patent/WO2015186037A1/en not_active Ceased
- 2015-05-29 KR KR1020167033551A patent/KR20170013261A/ko not_active Withdrawn
- 2015-05-29 CA CA2950527A patent/CA2950527A1/en not_active Abandoned
- 2015-05-29 ES ES15731117T patent/ES2747381T3/es active Active
- 2015-05-29 EA EA201692350A patent/EA201692350A1/ru unknown
- 2015-05-29 JP JP2016571161A patent/JP6622722B2/ja active Active
-
2019
- 2019-07-02 US US16/460,487 patent/US20200002768A1/en not_active Abandoned
-
2022
- 2022-02-17 US US17/651,481 patent/US12012636B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200002768A1 (en) | 2020-01-02 |
| AU2015270185A1 (en) | 2016-12-01 |
| EP3152327A1 (en) | 2017-04-12 |
| WO2015186037A1 (en) | 2015-12-10 |
| AU2015270185B2 (en) | 2018-07-05 |
| US12012636B2 (en) | 2024-06-18 |
| US20220389507A1 (en) | 2022-12-08 |
| CN106460059A (zh) | 2017-02-22 |
| CA2950527A1 (en) | 2015-12-10 |
| JP2017519498A (ja) | 2017-07-20 |
| US20170088897A1 (en) | 2017-03-30 |
| JP6622722B2 (ja) | 2019-12-18 |
| MX2016015930A (es) | 2017-04-11 |
| KR20170013261A (ko) | 2017-02-06 |
| EP3152327B1 (en) | 2019-06-26 |
| CN106460059B (zh) | 2021-07-13 |
| ES2747381T3 (es) | 2020-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012093361A5 (enExample) | ||
| IL260400B (en) | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | |
| BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
| WO2015176066A3 (en) | Lpa-associated protein and rna expression | |
| PH12016500331A1 (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
| HUE058219T2 (hu) | FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| EA201690456A1 (ru) | Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов | |
| EA201692497A1 (ru) | Биомаркеры ответа на ингибиторы ezh2 | |
| EA201690534A1 (ru) | Спироциклические соединения в качестве ингибиторов триптофангидроксилазы | |
| WO2015172085A3 (en) | Biomarkers for response to pi3k inhibitors | |
| EA201491371A1 (ru) | Соединение пиразинкарбоксамида | |
| MX2016015930A (es) | Biomarcador de hipertension pulmonar. | |
| MX372964B (es) | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) | |
| NZ714049A (en) | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds | |
| WO2012112315A3 (en) | Methods for diagnosis of kawasaki disease | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof | |
| IL290266A (en) | Biomarkers for determining the efficacy of immune checkpoint inhibitors | |
| EA201791424A1 (ru) | Получение белка | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| MX377026B (es) | Biomarcadores para la progresión de enfermedades en melanoma. | |
| WO2014187884A3 (en) | Mirnas as non-invasive biomarkers for heart failure | |
| MX2016006584A (es) | Métodos y composiciones para tratar los depósitos de amiloide. | |
| EA201790642A1 (ru) | Аллель-специфическая терапия для гаплотипов болезни хантингтона | |
| EA201891693A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови |